

PROGRAM

Updated: December 17, 2013

Session themes

Wednesday, March 5

- Plenary Session 1: Opening Ceremony with TAT 2014 Honorary Award Lecture and Keynote Lecture
- Plenary Session 2: Immunological Targets and Agents for Cancer Therapy
- Poster Viewing (1)
- Plenary Session 3: Phase 1 Studies, Miscellaneous Drugs and Targets
- Plenary Session 4: Cell Cycle Targets, CDK 4/6
- Poster Viewing (2)

Thursday, March 6

- Plenary Session 5: Preclinical Models in the Development of Cancer Therapeutics
- Plenary Session 6: Genomics in Early-Phase Drug Development
- Plenary Session 7: Problems in Early-Phase Drug Development
- Plenary Session 8: Miscellaneous Drugs and Targets

Friday, March 7

- Plenary Session 9: Inhibitors of Fibroblast Growth Factor Receptors
- Plenary Session 10: Methodological Issues in Drug Development of Targeted Agents
- Plenary Session 11: Drug Resistance to Targeted Agents

The TAT 2014 Program is subject to change. Check the congress website for the actual program version.

Wednesday, March 5**9:00-10:30 am****Plenary Session 1: Opening Ceremony***Chairs: Giuseppe Giaccone, Washington, DC & Jean -Charles Soria, Villejuif, France*

Opening addresses:

- On behalf of Organizing Committee – *Giuseppe Giaccone, Washington, DC*
- On behalf of Lombardi Cancer Center – *Louis Weiner, Washington, DC*
- On behalf of Cancer Network: Innovative pathways for drug approval for breast cancer – *Sandra Swain, Washington, DC*

Introduction "TAT 2014 Honorary Award Lecture"

Marinus Lobbezoo, Amsterdam, Netherlands

TAT 2014 Honorary Award Lecture

Patricia LoRusso, Detroit, MI

Keynote Lecture: Innovative ways to use the immune system to treat cancer

*Ira Mellman, South San Francisco, CA***10:30-11:00 am****Break****11:00 am -1:00 pm****Plenary Session 2: Immunological Targets and Agents for Cancer Therapy***Chairs: Michael Atkins, Washington, DC & Henk Verheul, Amsterdam, The Netherlands*

Immune checkpoint targets and their inhibitors: Review of anti-PD-1 antibodies under development

Julie Brahmer, Baltimore, MD

Immune checkpoint targets and their inhibitors: Review of Anti-PD-L1 antibodies under development

Speaker TBC

Predictive biomarkers for PD-1 pathway blockade

Michael Atkins, Washington, DC

Adoptive immunotherapy of cancer

*Steve Rosenberg, Bethesda, MD*Open slot for proffered paper - **Submit your abstracts!**

General Discussion

1:00-2:00 pm**Poster Viewing (1) & Lunch****2:00-3:45 pm****Plenary Session 3: Phase 1 Studies, Miscellaneous Drugs and Targets***Chairs: Filip Janku, Houston, TX & Udai Banerji, Sutton, UK*

TORERO: Phase 1 study of cetuximab plus temsirolimus in patients with advanced solid tumors

Jean -Charles Soria, Villejuif, France

TAX-TORC: TORC1/2 inhibitor AZD2014 plus paclitaxel

*Udai Banerji, Sutton, UK*Further slots are still open for phase 1 studies (completed or ongoing) with new drugs or combinations of current interest - **Submit your abstracts!**

3:45-4:15 pm
Break

4:15-6:00 pm

Plenary Session 4: Cell Cycle Targets, CDK 4/6

Chairs: Geoffrey Shapiro, Boston, MA & Gary Schwartz, New York, NY

Educational introduction: Biology of cell cycle targets
Geoffrey Shapiro, Boston, MA

Palbociclib (PD-033299) in breast cancer
Angela DeMichele, Philadelphia, PA

LEE011 - preclinical and phase I data for a novel CDK4/6 inhibitor
Samit Hirawat, East Hanover, NJ

LY2835219
Speaker TBC

General discussion

6:00-7:15 pm

Poster Viewing (2) & Welcome Reception

Thursday, March 6

8:30-10:30 am

Plenary Session 5: Preclinical Models in the Development of Cancer Therapeutics

Chairs: Heiner Fiebig, Freiburg, Germany & Emile Voest, Utrecht, Netherlands

Patient-derived tumor models
Heiner Fiebig, Freiburg, Germany

Incorporation of tumor organoids or PDX in clinical trials, how personalized can we be?
Emile Voest, Utrecht, Netherlands

Cellular re-programming
Richard Schlegel, Washington, DC

Genetically-engineered mouse models
Kwok-Kin Wong, Boston, MA

General discussion

10:30-11:00 am

Break

11:00-12:50 am

Plenary Session 6: Genomics in Early-Phase Drug Development

Chairs: Peter O'Dwyer, Philadelphia, PA & Patricia LoRusso, Detroit, MI

Verbal report of the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT) meeting: Genomics-based early-phase clinical trials in oncology
Giuseppe Giaccone, Washington, DC

Genomic sequencing in early-phase drug development (review)
Speaker TBC

Challenges of genomic genotyping and trial development and initiation
Speaker TBC

Deep sequencing in the phase 1 setting
Gary Palmer, Cambridge, MA

SHIVA trial, a randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer
Christophe Le Tourneau, Paris , France

General discussion

12:50 am - 1:50 pm

Lunch

1:50-3:40 pm

Plenary Session 7: Problems in Early-Phase Drug Development

Chairs: Anthony Tolcher, San Antonio, TX & Chris Twelves, Leeds, UK

Session introduction

Anthony Tolcher, San Antonio, TX

Example 1: PI3K inhibitors

Josep Tabernero, Barcelona, Spain

Correlating signalling inhibition and cell growth for AKT and MEK inhibitor combinations

Udai Banerji, Sutton, UK

Example 2: Hsp90 inhibitors

Len Neckers, Bethesda, MD

Example 3: PARP inhibitors

Ruth Plummer, Newcastle, UK

General discussion

3:40-4:10 pm

Break

4:10-6:10 pm

Plenary Session 8: Miscellaneous Drugs and Targets

Chairs: Gail Eckhardt, Aurora, CO & Jourik Gietema, Groningen, Netherlands

MDM2-targeting agents

Gary Schwartz, New York, NY

MET inhibitors

Donald Bottaro, Bethesda, MD

SMAC mimetics

Christina Annunziata, Bethesda, MD

Drugging the undruggable: Small molecule protein - protein interaction inhibitors

Jeffrey Toretsky, Washington, DC

Awarded poster presentation (1)

*Presenter TBA - **Submit your abstracts!***

Awarded poster presentation (2)

*Presenter TBA - **Submit your abstracts!***

General discussion

Friday, March 7

8:30-10:10 am

Plenary Session 9: Inhibitors of Fibroblast Growth Factor Receptors

Chairs: Jean -Charles Soria, Villejuif, France & TBC

FGFR1: RNA, DNA and protein correlations
Ross Camidge, Aurora, CO

Review of clinical development programs
Jean -Charles Soria, Villejuif, France

Translating therapeutic potential of AZD4547, a potent and selective inhibitor of FGFR 1, 2 and 3
Nigel Brooks, Macclesfield, Cheshire, UK

Phase 1 development of BGJ398
Speaker TBC

General discussion

10:10-10:30 am

Break

10:30-12:10 am

Plenary Session 10: Methodological Issues in Drug Development of Targeted Agents

Chairs: Filippo de Braud, Milan, IT & Anthony Chan, Hong Kong

Liquid biopsies vs. serial tissue biopsies
Carlos Caldas, Cambridge, UK

Circulating microRNA as "liquid biopsies" to assess drug effects on targetable pathways
Anton Wellstein, Washington, DC

Worldwide collaboration in molecular profiling
Lillian Siu, Toronto, ON, Canada

Regulatory guidance for development of molecular diagnostics and targeted therapeutics for cancer
Speaker TBC

General discussion

12:10 am - 1:00 pm

Lunch

1:00-3:00 pm

Plenary Session 11: Drug Resistance to Targeted Agents

Chairs: Giuseppe Giaccone, Washington, DC & Susan Bates, Bethesda, MD

Intratumoral heterogeneity
Charles Swanton, London, UK

Bioinformatics to design rational combinations of targeted agents
Bissan Al-Lazikani, Sutton, UK

Combination treatment on the basis of mechanisms of unresponsiveness
Speaker TBC

Mechanisms of resistance to EGFR targeted antibodies
Louis Weiner, Washington, DC

Microenvironment-mediated resistance to targeted therapies
Arne Östman, Stockholm, Sweden

General discussion

3:00-3:10 pm

Closing remarks / preview of TAT 2015

Giuseppe Giaccone, Washington, DC